Abstract
Depression is a common mental disease, and it is one of the most crippling diseases in the world. Although current pharmacotherapies contribute to the treatment of depression, the high incidence of a partial responses or no responses, and delayed onset of the antidepressants, make many patients to experience unsatisfactory results from treatment. In view of the high suicide rate during the period of drug onset, it is critical to find antidepressant drugs with rapid onset for the treatment of depression. This paper mainly reviews some drugs that have rapid antidepressant effect and their mechanisms, including monoaminergic receptor drugs, glutamate receptor drugs, mammalian target of rapamycin (mTOR) signaling agonist, gamma-aminobutyric acid energy (GABAergic) agonist and drug combinations. In addition, we introduce several rodent models currently used to assess antidepressant onset in this review: chronic unpredictable mild stress (CUMS), forced swimming test (FST) and tail suspension test (TST), olfactory bulbectomy (OBX) and other models, which provide a methodological approach for assessing the rapid onset of antidepressant drugs.
Keywords: Rapid onset, antidepressants, animal models, depression, chronic unpredictable mild stress (CUMS), suspension test.
Current Pharmaceutical Design
Title:Current Rapid-Onset Antidepressants and Related Animal Models
Volume: 24 Issue: 22
Author(s): Kuo Yan, Yi-Bing Chen, Jia-Rong Wu, Kuang-Dai Li and Yuan-Lu Cui*
Affiliation:
- Research Center of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, No. 88 YuQuan Road, Nankai District, Tianjin, 300193,China
Keywords: Rapid onset, antidepressants, animal models, depression, chronic unpredictable mild stress (CUMS), suspension test.
Abstract: Depression is a common mental disease, and it is one of the most crippling diseases in the world. Although current pharmacotherapies contribute to the treatment of depression, the high incidence of a partial responses or no responses, and delayed onset of the antidepressants, make many patients to experience unsatisfactory results from treatment. In view of the high suicide rate during the period of drug onset, it is critical to find antidepressant drugs with rapid onset for the treatment of depression. This paper mainly reviews some drugs that have rapid antidepressant effect and their mechanisms, including monoaminergic receptor drugs, glutamate receptor drugs, mammalian target of rapamycin (mTOR) signaling agonist, gamma-aminobutyric acid energy (GABAergic) agonist and drug combinations. In addition, we introduce several rodent models currently used to assess antidepressant onset in this review: chronic unpredictable mild stress (CUMS), forced swimming test (FST) and tail suspension test (TST), olfactory bulbectomy (OBX) and other models, which provide a methodological approach for assessing the rapid onset of antidepressant drugs.
Export Options
About this article
Cite this article as:
Yan Kuo, Chen Yi-Bing , Wu Jia-Rong, Li Kuang-Dai and Cui Yuan-Lu *, Current Rapid-Onset Antidepressants and Related Animal Models, Current Pharmaceutical Design 2018; 24 (22) . https://dx.doi.org/10.2174/1381612824666180727115222
DOI https://dx.doi.org/10.2174/1381612824666180727115222 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and Antitumor Activity of New Pyrimidine and Caffeine Derivatives
Letters in Drug Design & Discovery Exploring the Mitochondrial Apoptotic Cell Death Landscape and Associated Components Serving as Molecular Targets, Primarily for Synthetic and Natural Drugs Targeting Oncology Therapeutics
Current Molecular Pharmacology A Bias in the Reading of the Genetic Code of <i>Escherichia coli</i> is a Characteristic for Genes that Specify Stress-induced MazF-mediated Proteins
Current Genomics Muscarinic Receptors as a Target for Drugs Treating Schizophrenia
Current Drug Targets - CNS & Neurological Disorders Cutting through the Complexities of mTOR for the Treatment of Stroke
Current Neurovascular Research η-Secretase: Reduction of Amyloid Precursor Protein η-Site Cleavage in Alzheimers Disease
Current Alzheimer Research Chronic Deposition of Aβ Influences Microcirculation in the Chronic Stage of Cerebral Ischemia
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Beta-Amyloid, Oxidative Stress and Down Syndrome
Current Alzheimer Research Synthesis, Characterization, and Molecular Structure of a Novel Zinc (II) Complex: Assessment of Impact of MDR1Pgp Expression on its Cytotoxic Activity
Medicinal Chemistry Homocysteine and Hyperhomocysteinaemia
Current Medicinal Chemistry The Genetic Components of Alcohol and Nicotine Co-Addiction: From Genes to Behavior
Current Drug Abuse Reviews Experimental Research on Nitric Oxide and the Therapy of Alzheimer Disease: A Challenging Bridge
CNS & Neurological Disorders - Drug Targets Understanding the Monoclonal Antibody Involvement in Targeting the Activation of Tumor Suppressor Genes
Current Topics in Medicinal Chemistry Scyphomedusae of the Mediterranean: State of the Art and Future Perspectives
Central Nervous System Agents in Medicinal Chemistry Serotonin and Cognitive Flexibility: Neuroimaging Studies into the Effect of Acute Tryptophan Depletion in Healthy Volunteers
Current Medicinal Chemistry Buprenorphine and Methadone Maintenance Treatment - Sexual Behaviour and Dysfunction Prevalence
Letters in Drug Design & Discovery Child and Adolescent Mental Health in Pakistan
Adolescent Psychiatry Editorial (The Popularity of “Legal Highs”)
Current Drug Abuse Reviews Tobacco Smoking and Association between Betel Nut Chewing and Metabolic Abnormalities Among Military Males: The CHIEF Study
Endocrine, Metabolic & Immune Disorders - Drug Targets The Regulatory Roles of Mitogen-Activated Protein Kinase (MAPK) Pathways in Health and Diabetes: Lessons Learned from the Pancreatic β-Cell
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)